Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 1999

View Archived Issues

AstraZeneca takes an ambitious approach to drug R&D

HIV-VAC's AIDS vaccine progressing in clinical trials in Russia

New class of antidiabetic agents under study at Novo Nordisk

Boehringer Ingelheim assumes full responsibility for continued development of novel antitumor agent

Hypoxanthine derivatives from NeoTherapeutics useful for depression, obesity, etc.

Mallinckrodt's MRI contrast agent approved for marketing in U.S.

ImmunoGen's lead tumor-activated prodrug enters the clinic

"Inactive" pharmaceutical excipient demonstrates potent anti-HSV activity in vitro and in vivo

Ribozyme to form joint venture with Elan for breast cancer therapeutic

Water-soluble mesilate salt form of known antitumor agent prepared at Pfizer

Antiproliferative agents derived from vegetable oil in development at PharmaScience

Medivir investigates new treatments for hepatitis B

A6/cyclophosphamide combination to be studied as antimetastatic therapy

HU-308: a potent and specific agonist at the peripheral cannabinoid receptor

AHP denies rumors of merger talks with P&U

Zambon initiates phase II trial of Sheffield's MSI albuterol

Vion's TAPET administered to first patients intratumorally in phase I trial

HGF gene therapy for acute GVHD: studies in mice

AEterna presents promising phase I data for AE-941 in AMD

KRN-7000-stimulated human cells effective in vitro against melanoma cell lines

Cypress Bioscience and Medexus enter agreement for Prosorba Column in Canada

New chikungunya virus vaccine safe and highly immunogenic in humans

Recombinant HEV vaccine: safety and immunogenicity in monkeys and humans

PPL Therapeutics announces promising preliminary data from AAT deficiency trial

Lorus Therapeutics cleared to initiate clinical trials of GTI-2040

Merck KGaA finalizes Theramex acquisition

Potent new anticonvulsants emerge from China

Versicor achieves milestone in antibacterial collaboration with Novartis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....